Among the technologies attracting significant interest, antibody-drug complexes (ADCs) have emerged as one of the most closely watched developments in oncology.
ADCs combine three main components: a monoclonal antibody that targets cancer cells, a cytotoxic payload, and a specialized ligand that connects the two. Once the antibody binds to the cancer cell, the payload is released directly into the target site.
This targeted delivery mechanism seeks to improve treatment accuracy while limiting damage to healthy tissue, potentially reducing side effects associated with conventional chemotherapy.
ADCs were a major topic of discussion at the recent American Society of Clinical Oncology (ASCO) annual meeting, reflecting the growing scientific and clinical interest in this method. Although this concept has been around for decades, technological advances have enabled broader development and application across multiple cancer types.
Today, several advanced centers have received regulatory approval in Europe, while approximately 400 additional candidates are being developed globally, including several late-stage clinical programs. Of these, dozens of programs have advanced to phase III clinical trials, highlighting the scale of ongoing research and investment.
Gilead’s acquisition of Tupolis, valued at approximately $3.15 billion upfront, underscores the industry’s continued conviction in targeted drug delivery technologies designed to improve efficacy while minimizing off-target toxicity.
